Price$7.00-0.34 (-4.70%)
01:30 PM07:45 PM
News · 26 weeks57-76%
2025-12-142026-06-07
Mix2690d
- SEC Filings11(42%)
- Insider7(27%)
- Other5(19%)
- Earnings2(8%)
- Leadership1(4%)
Latest news
25 items- PRArvinas Joins The Michael J. Fox Foundation's LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson's DiseaseNEW HAVEN, Conn., June 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has recently joined the LRRK2 Investigative Therapeutics Exchange (LITE) program and the Parkinson's Precision Medicine Initiative (PPMI), both supported by The Michael J. Fox Foundation for Parkinson's Research (MJFF). Participation in these programs will support advancement of ARV-102, Arvinas' investigational, orally bioavailable and brain-penetrant PROTAC designed to specifically target and degrade leucine-rich repeat kinase 2 (LRRK2) for the potential treatment of neurodegenerative diseases, in
- SECArvinas Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ARVINAS, INC. (0001655759) (Filer)
- PRArvinas to Present at Jefferies Global Healthcare ConferenceNEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET. A live audio webcast of the presentation will be available here and under "Events and Presentations" on the Investors and Media section of the Company's website. About ArvinasArvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its P
- INSIDERPresident and CEO Teel Randy sold $19,962 worth of shares (2,209 units at $9.04), decreasing direct ownership by 0.77% to 285,009 units (SEC Form 4) (tax liability)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERChief Financial Officer Saik Andrew sold $110,693 worth of shares (11,139 units at $9.94), decreasing direct ownership by 5% to 193,128 units (SEC Form 4) to satisfy withholding obligation4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERChief Scientific Officer Cacace Angela M sold $95,965 worth of shares (9,657 units at $9.94), decreasing direct ownership by 5% to 182,966 units (SEC Form 4) to cover withholding tax4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERVP, Chief Accounting Officer Loomis David K sold $19,070 worth of shares (1,919 units at $9.94), decreasing direct ownership by 5% to 40,193 units (SEC Form 4) to satisfy withholding tax4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERChief Medical Officer Berkowitz Noah sold $110,385 worth of shares (11,108 units at $9.94), decreasing direct ownership by 5% to 191,395 units (SEC Form 4) (withholding obligation)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERPresident and CEO Teel Randy sold $95,965 worth of shares (9,657 units at $9.94), decreasing direct ownership by 3% to 287,218 units (SEC Form 4) (withholding tax)4 - ARVINAS, INC. (0001655759) (Issuer)
- SECArvinas Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ARVINAS, INC. (0001655759) (Filer)
- SECArvinas Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ARVINAS, INC. (0001655759) (Filer)
- PRArvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update– First-ever FDA approved PROTAC supports the further development and potential of Arvinas' pipeline – – Announced FDA Approval of VEPPANU™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer – – Announced selection of Rigel Pharmaceuticals for the exclusive global rights to VEPPANU – – Presented ARV-102 (LRRK2 degrader) Phase 1 clinical data in patients with Parkinson's disease demonstrating reduction in endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy – – Presented ARV-6723 (HPK1 degrader) preclinical data at the American Associated of Cancer Research Annual meeting demonstrating the potential
- PRArvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on net sales – NEW HAVEN, Conn., May 12, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, and Pfizer Inc. (NYSE:PFE) have entered into a license agreement with Rigel Pharmaceuticals, Inc., a commercial stage biotechnology company focused on hematologic disorders and cancer, for the exclusive global development, manufacturing, and commercialization rights for VEPPANU™ (vepdegestrant). VEPPANU is the
- SECSEC Form 10-Q filed by Arvinas Inc.10-Q - ARVINAS, INC. (0001655759) (Filer)
- SECSEC Form 144 filed by Arvinas Inc.144 - ARVINAS, INC. (0001655759) (Subject)
- SECSEC Form 144 filed by Arvinas Inc.144 - ARVINAS, INC. (0001655759) (Subject)
- PRArvinas to Report First Quarter 2026 Financial Results on May 12, 2026NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, May 12, 2026 at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About Arvinas Arvinas (NASDAQ:ARVN) is a biotechnology company dedicated to improving the lives of patients
- SECArvinas Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ARVINAS, INC. (0001655759) (Filer)
- PRArvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer– VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader – – Approval received in advance of FDA-assigned PDUFA date of June 5, 2026; Arvinas and Pfizer remain on track to announce selection of a third party – – VEPPANU offers a new therapeutic option in ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, where treatment resistance remains a major clinical challenge – NEW HAVEN, Conn., May 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), today with its partner Pfizer Inc. (NYSE:PFE), announced that the U.S. Food and Drug Administration (FDA) has granted approval for VEPPANU (vepdegestrant) for the treatment of adults with est
- SECSEC Form DEFA14A filed by Arvinas Inc.DEFA14A - ARVINAS, INC. (0001655759) (Filer)
- SECSEC Form DEF 14A filed by Arvinas Inc.DEF 14A - ARVINAS, INC. (0001655759) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Arvinas Inc.SCHEDULE 13G/A - ARVINAS, INC. (0001655759) (Subject)
- INSIDERSEC Form 4 filed by Berkowitz Noah4 - ARVINAS, INC. (0001655759) (Issuer)
- SECArvinas Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ARVINAS, INC. (0001655759) (Filer)
- PRArvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy – – ARV-102 was well tolerated across all dose levels following 28 days of once-daily dosing – – Data support further development of ARV-102 in additional neurodegenerative diseases characterized by lysosomal dysfunction, including progressive supranuclear palsy, a rapidly progressing and devastating tauopathy – – Data presented during an oral session at the Alzheimer's and Parkinson's Diseases and Related Neurological Disorders Conference – NEW HAVEN, Conn., March 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology
ARVN FAQ
7 questionsWhat does Arvinas Inc. do?
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The...Where does ARVN stock trade?
Arvinas Inc. (ARVN) is listed on NASDAQ.What sector and industry is ARVN in?
Arvinas Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Arvinas Inc. go public?
Arvinas Inc. (ARVN) completed its IPO in 2018.What are analysts saying about ARVN?
Arvinas Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy with a $1500.00 price target on 2026-01-06. Recent price targets range from $600.00 to $1600.00.What companies are similar to ARVN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ARVN side-by-side with any of them on Quantisnow.How can I track ARVN on Quantisnow?
Quantisnow aggregates Arvinas Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARVN to receive live email and push alerts on every new disclosure.